Treatment with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARBs) prevents the progression of CKD in both people with and without diabetes and reduces urine albumin excretion [16]. This evidence concerns the gene ACE and chronic kidney disease.